Together, these findings suggest that combining tau-PET with meta-analytical task-fMRI maps of major cognitive functions improves the prediction of domain-specific cognitive decline compared to conventional global/temporal-lobe tau-PET measures in AD. The gene discussed is MAPT; the disease is Alzheimer disease.